The DOI matches its Crossref record.
Clinical outcomes after initial pseudomonas acquisition in cystic fibrosis
Abstract
Summary: Objectives: To evaluate clinical outcomes associated with initial isolation of Pseudomonas aeruginosa ( Pa ) in a large U.S. cystic fibrosis (CF) cohort in the current era of widespread early Pa eradication therapy. Methods: Participants were children with CF enrolled in the Early Pseudomonas Infection Control (EPIC) Observational Study who had no isolation of Pa from respiratory cultures prior to enrollment. Population‐averaged regression models using generalized estimating equation methods were used to estimate the effect of Pa acquisition on endpoints including lung function, growth, pulmonary exacerbation rate, respiratory signs and symptoms, and respiratory cultures. Results: Eight hundred thirty‐eight subjects were observed for a mean 4.6 (SD 1.2) years during which 431 (51%) acquired Pa . There was no statistically significant effect of Pa acquisition on the slopes of FEV 1 % predicted or growth parameters. Pulmonary exacerbation rate was statistically significantly greater after Pa acquisition (incident rate ratio 1.40, 95% CI 1.07, 1.84) as were odds of crackles or wheeze on physical exam (OR 1.23, 95% CI 1.00, 1.52). Odds of isolation of MRSA (OR 1.86, 95% CI 1.38, 2.49) and S. maltophilia (OR 2.11, 95% CI 1.49, 2.98) increased after Pa acquisition, while the odds of H. influenzae (OR 0.54, 95% CI 0.46, 0.64) decreased. Conclusions: In this large U.S. cohort, we did not detect an association between acquisition of Pa and deterioration in lung function or nutrition. Pa acquisition was associated with significantly increased pulmonary exacerbation rate and odds of crackles or wheeze. Pa infection may be the cause of these outcomes or a marker of more severe disease. Pediatr Pulmonol. 2015; 50:42–48. © 2014 The Authors. Pediatric Pulmonology Published by Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bacteriocin acts on preformed biofilms and may prevent them from forming [1].”
From The effect of nisin on the biofilm production, antimicrobial susceptibility and biofilm formation of Staphylococcus aureus and Pseudomonas aeruginosa (2022) · cites this paper as [1]
In the citing paper
“Furthermore, it can be used with antibiotics to treat patients infected with antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus aureus and as an agent to control biofilm formation by S. aureus and other pathogens [1].”
From The effect of nisin on the biofilm production, antimicrobial susceptibility and biofilm formation of Staphylococcus aureus and Pseudomonas aeruginosa (2022) · cites this paper as [1]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 24
- 10.1164/rccm.200304-505SO · DOI · Paper page
- 10.1001/jama.293.5.581 · DOI · Paper page
- 10.1016/j.jpeds.2007.03.006 · DOI · Paper page
- 10.1002/ppul.1950120306 · DOI · Paper page
- 10.1097/00063198-200311000-00008 · DOI
- 10.1016/j.jcf.2012.10.004 · DOI · Paper page
- 10.1016/j.jcf.2009.03.001 · doi:10.1016/j.jcf.2009.03.001
- 10.1016/S0022-3476(09)90007-5 · DOI
- 10.1002/ppul.2009 · doi:10.1002/ppul.2009
- 10.1002/ppul.10127 · DOI · Paper page
- 10.1164/rccm.200710-1599OC · DOI
- 10.1002/ppul.21417 · doi:10.1002/ppul.21417
- 10.1016/j.jcf.2012.04.003 · doi:10.1016/j.jcf.2012.04.003
- 10.1016/j.cct.2009.01.003 · DOI
- 10.1016/j.jpeds.2008.05.005 · DOI · Paper page
- 10.1002/ppul.1950150204 · DOI · Paper page
- Kuczmarski RJ, 2002, CDC Growth Charts for the United States: methods and development, Vital Health Stat, 11, 1
- 10.1164/ajrccm/148.6_Pt_1.1502 · DOI
- 10.1164/ajrccm.159.1.9712108 · DOI · Paper page
- 10.1002/ppul.21374 · DOI · Paper page
- 10.1002/ppul.21525 · DOI
- 10.1001/archpediatrics.2011.136 · DOI · Paper page
- 10.1002/ppul.22693 · DOI
- 10.1002/(SICI)1099-0496(199911)28:5<321::AID-PPUL3>3.0.CO;2-V · doi:10.1002/(sici)1099-0496(199911)28:5<321::aid-ppul3>3.0.co;2-v
Cited by
Physiology and pathophysiology of human airway mucus
Hill, D. B., Button, B., Rubinstein, M., & Boucher, R. C. (2022) · Physiological Reviews · doi:10.1152/physrev.00004.2021 · Cited by 366
Cystic Fibrosis Lung Disease: An Overview
Turcios, N. L. (2020) · Respiratory Care · doi:10.4187/respcare.06697 · Cited by 217
Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis
Smith, S., Rowbotham, N. J., & Regan, K. H. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001021.pub3 · Cited by 92
Ghapanvari, P., Taheri, M., Jalilian, F. A., Dehbashi, S., Dezfuli, A. A. Z., & Arabestani, M. R. (2022) · European Journal of Medical Research · doi:10.1186/s40001-022-00804-x · Cited by 38
Metadata
- Authors
- Zemanick, E. T., Emerson, J., Thompson, V., McNamara, S., Morgan, W., Gibson, R. L., Rosenfeld, M., & the EPIC Study Group
- Venue
- Pediatric Pulmonology
- Publisher
- Wiley
- Published
- 2014-03-18
- Volume
- 50
- Issue
- 1
- Pages
- 42-48
- ISSN
- 8755-6863
- 1099-0496
- Cited by
- 65
- References
- 0
- Language
- en
- Funders
- Cystic Fibrosis Foundation Grants (OBSERV04K0, EPIC0K0)
- Clinical Trials Registration (NCT00097773)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical outcomes after initial pseudomonas acquisition in cystic fibrosis. https://app.cochat.ai/papers/10.1002/ppul.23036
- The paper
- Zemanick, E. T., Emerson, J., Thompson, V., McNamara, S., Morgan, W., Gibson, R. L., Rosenfeld, M., & the EPIC Study Group. (2015). Clinical outcomes after initial pseudomonas acquisition in cystic fibrosis. Pediatric Pulmonology. https://doi.org/10.1002/ppul.23036
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.